CME
Optimizing Treatment Selection and Side Effect Management in BRAF-Mutant Melanoma
Host: Jeffrey S. Weber, MD, PhD
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination t